Oncogenic RAS drives resistance to pemigatinib in cholangiocarcinoma harboring a FGFR2 delins disrupting ligand binding.

Mir Lim, Patrick T Lynch, Xiaochen Bai, David Hsiehchen†. Oncogenic RAS drives resistance to pemigatinib in cholangiocarcinoma harboring a FGFR2 delins disrupting ligand binding. JCO Precision Oncology. 2023.